Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

Completed

Conditions studied: Coronary Artery Disease

In brief

Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease. The specific aim of the proposed study is to determine whether the interaction between proton-pump inhibitors (PPIs) and clopidogrel is dependent on CYP2C19 haplotype.

Key facts

Study ID

NCT01094275

Run by

Neil Kleiman, MD

People needed

75

Starts

2010-01-01

Expected to finish

2014-06-30

Last updated by the study team

2018-01-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18- 65
• healthy - not taking any drugs / over the counter drugs regularly.
• ability and commitment to take the drugs and volunteer for 3 blood draws.

You may not qualify if…

• Taking any scheduled medication known to affect platelet function such as clopidogrel or NSAIDS11, COX2 inhibitors, beta blockers, calcium channel blockers, diuretics, anti-coagulants, older psychotropic agents, and recent ingestion of alcohol and caffeine
• Known history of heart disease
• Bleeding disorders
• Known allergy or contraindications to omeprazole or clopidogrel
• Pregnant and nursing women will also be excluded.

Where it is running

• The Methodist Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.